http://rdf.ncbi.nlm.nih.gov/pubchem/patent/UA-63153-U
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a444065ee5bcabe93d6576967aafb6f1 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B17-42 |
| filingDate | 2011-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7186b6c837723ccea684dd876ebee979 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef0288e9cc4a6122f271b34f8aaa58c7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21d3fe79ee25ebd284f863eb0fab0fb5 |
| publicationDate | 2011-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | UA-63153-U |
| titleOfInvention | METHOD FOR PREVENTION OF FAILURES AND SYNDROME OF OVARIAN HYPERSTIMULATION IN AUXILIARY REPRODUCTIVE TECHNOLOGIES |
| abstract | A method for the prevention of failures and ovarian hyperstimulation syndrome during assisted reproductive technologies involves performing, starting from the 2nd day of the menstrual cycle, a course of intramuscular injections of the drug follicle-stimulating hormone. After the follicle is identified, a subcutaneous injection of a gonadotropin releasing hormone antagonist is administered, an ovulatory dose of the human chorionic gonadotropin preparation is injected, the oral administration of a selective agonist of β2-dopamine quinagolide receptors is performed, and transvaginal follicle puncture is performed for egg collection. After an injection of human chorionic gonadotropin, dynamic progesterone levels are monitored. During transvaginal puncture of the follicles, one intravenous injection of 0.2 mg of terlipressin is performed. |
| priorityDate | 2011-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 18.